about the membership
Save time staying up-to-date, generate ideas, and become a better mentor with exclusive, easy-to-read content. Ask your company or library to support your growth with a Drug Hunter membership.
molecules of the month
Easy-to-read slide decks and summaries explaining molecules in more depth, with context.
February’s molecule, the Novartis factor B inhibitor LNP023, targets the serine protease factor B (FB), a key node in the complement system. The complement part of the innate immune system is a hot area for drug discovery due to its increasingly recognized role in a wide range of chronic human diseases, including age-related macular degeneration (AMD). The authors took a pathway approach to drugging a portion of the complement system called the “alternative complement pathway” (AP), evaluating three different targets including FB. While proteases are tough drug targets due to their typically polar and frequently conserved active sites, the Novartis team was able to develop an oral, reversible, blood-retinal-barrier penetrant clinical candidate from a weak (10 uM) fragment identified through biochemical screening. While LNP023 doesn’t appear to have entered development for the treatment of ocular diseases, it is currently in multiple Ph. II studies for nephropathies.
The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353), was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg QD) despite having two basic amines (dibasic). Interestingly for a chronically administered drug, the molecule is noted to have QT prolongation risk at ~3x the recommended dose (450 mg), which appears acceptable for this rare and underserved indication. The molecule was discovered after a structure-based drug design campaign starting with knowledge from a previously poorly bioavailable benzamidine-containing zwitterion, avoralstat (BCX4161). The benzamidine was successfully replaced with a similarly basic benzylamine, and the new benzylamine-containing fragment was elaborated into molecule with a highly dissimilar structure and binding mode from the original drug. There are several interesting features from the crystal structures including the fact that the highly hydrophilic primary amine is buried in a polar cleft of the protein. This approved drug is another great example of a “rule-breaker” succeeding in a rare disease setting.
The Biogen compound BIO-32546 is a potent (IC50 = 1 nM), selective, oral, non-zinc-binding reversible autotaxin (ATX) inhibitor, and is an interesting example of a relevantly large brain-penetrant zwitterion. The molecule has a distinct structure from ATX inhibitors previously highlighted (e.g. Small Molecules of the Month May, Jul., Nov. 2020) and was derived from an phosphonic acid-containing inhibitor hit (28 nM) from a lipid mimetic chemical library. If your first reaction was that this molecule looks like an S1P modulator, you’re not crazy – the chemical library was derived from Biogen’s S1P program. Optimization was guided by cocrystal structures and the window against a hERG liability (surprising for an acid-containing molecule) was mitigated with introduction of a benzylic methyl group. The compound demonstrated in vivo efficacy in a model of acute pain with good PK/PD correlation in a model of acute pain. No brain-penetrant ATX inhibitors appear to be in clinical trials, and Biogen doesn’t appear to have advanced an ATX inhibitor into the clinic.
Get early and exclusive access to new reference material, new articles, events and new opportunities.
and much more
Save hours staying up-to-date, generate ideas, and grow as a mentor with exclusive access to:
- Molecules of the Month slide decks
- Molecules of the Month in-depth summaries
- Exclusive reference pages
- Exclusive articles
- Early content releases
- Early access to new features
Frequently Asked Questions
Premium Molecules of the Month slide decks are found linked on every Molecules of the Month page and unlocked when logged in. Recent individual molecule pages also have in-depth information that is site-searchable. Recent premium-only articles and slide decks can be found on the Premium page in the navigation menu.
Yes, a receipt is provided with each membership subscription, and custom invoices for company reimbursement can be obtained downloaded directly from the account page online or by contacting email@example.com.
Companies, research sites, or departments can purchase access for groups of 5+ users at discounted rates either through coupons for individuals paid by the institution, or through a corporate account which can easily grant access to subaccounts by company e-mail address.
A large pharma head of research told us her subscription saves her days, if not weeks of time each month. Consider also the value of getting to a candidate faster with an empowered team, and the cost of a single compound or assay that could be avoided with more context.
Between time savings and the value of enriched ideas, it’s more expensive not to have a subscription!
We’re happy to help set up a demo for your team – just contact us at firstname.lastname@example.org
No, all payments are handled by industry-leading third parties such as Stripe or Plaid. We do not store or handle your sensitive information. See Stripe’s documentation for more information: (https://stripe.com/docs/security/stripe)
Yes, please reach out to email@example.com to get a tailored solution for your organization.
We can work directly with your academic library to set up institutional access. If your library will not cover a subscription, contact us at firstname.lastname@example.org and we may be able to offer a student rate to verified students.
Companies can pay by credit or debit card, ACH transfer, wire transfer, or check for annual subscriptions. We’ll work directly with your accounting team to get your team set up!
You can cancel your monthly subscription at any time online using the membership portal, and cancellations will reflect in the next billing cycle. Annual plans that are cancelled will also not renew on the next billing cycle.
“Drug Hunter has a great overview of what is happening in our field, saves time on scouring through news feeds, literature and irrelevant stuff that comes up. It is a tool specifically for people like me to weed out the noise. Big time saver.”
Drug Discovery Scientist, Denali Therapeutics / Publicly Listed Biotech
“I look forward to reading the summaries that come out every month. It helps me keep up to date on what’s going on in the industry.”
Senior Director, Head of Medicinal Chemistry, Eikon Therapeutics / VC-Backed Biotech
“When I need to find information, I know that I can find it on Drug Hunter. This is what was always missing in our field. I’ve been designing drugs for years and the most frustrating part is learning on your own. You may need to go through hundreds of articles to find the information you need. Drug Hunter cuts down on a lot of this!”
Associate Director, Drug Discovery, Essa Pharma / Publicly Listed Biotech
“Drug Hunter helps keep me up to date with the scientific literature and saves me so much valuable time. Please continue the excellent work!”
Senior Director of Medicinal Chemistry, Protagonist Therapeutics / Publicly Listed Biotech
“The thing I like most about it is the concise, to-the-point presentation of the relevant information in an easily digestible format, that is readily accessible to all, from experienced drug hunters to scientists who are just starting their careers. The time-savings achieved by using Drug Hunter are another major selling point. Keep up the good work, folks!”
Executive Director, Science and Strategy Advisor, Astellas Pharma
“I like Drug Hunter! I realize that the team puts so much time and effort into this work and it is not easy work. It is a key opinion leader in the industry. I want Drug Hunter to go on forever. It’s really good!”
Founder and CEO, Arum Therapeutics / Privately Held Biotech
“Drug Hunter is really good at summarizing all of the key information. It really helps me understand and digest things!”
Senior Scientist, Drug Discovery, Genentech
“The cheat sheets that are published are great. Having a centralized resource of those is super helpful. When I recently onboarded a new team member, I taught her about Topliss trees using Drug Hunter. I am way more on top of the med. chem literature because of Drug Hunter!”
Senior Scientist, Medicinal Chemistry, Vividion Therapeutics
“I don’t know of anything similar to this. It’s great that I can visit the site and get a pointer to recent important papers in the field. With the article annotations, I also get a perspective I may not get just by reading papers myself.”
Computational Chemist, PostEra
“I know I can find new information, targets, and compounds on Drug Hunter each month, which has been really helpful. It’s a good website to see the latest news in drug discovery!”
Senior Group Leader, Pharmaron
“Drug Hunters highly informed, relevant science, category-leading approach is time saving, cost saving and importantly a consistent source of inspiration for new Product Development programs. More like this please Drug Hunter!”
Director of Business Development, Pharmalex
“I like that Drug Hunter shows condensed information about what is at the forefront of medicinal chemistry at the moment. The molecules are great, I would otherwise have to sift through a lot of articles to find these drugs. I am very satisfied with Drug Hunter.”
Medicinal Chemist, RAPT Therapeutics / Publicly Listed Biotech
As both an academic and (most recently) an industrial medicinal chemist, the Drug Hunter resources have been very helpful so far. I’ve passed along several of the excellent primer/cheat sheets to my own students, and the lists of CROs and investors have been helpful for company building. Of course, the Molecules of the Month, and the deep science and strategy behind their structures shared in…
Academic, Industrial Chemist
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Eli Lilly
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Novo Nordisk
- Merck KGaA
- Celgene (BMS)
- Biogen |Astellas
- Daiichi Sankyo
- Kyowa Kirin
- LEO Pharma
- RA Capital
- ARCH Venture Partners
- MPM Capital
- The Column Group
- 5AM Ventures
- Versant Ventures
- Goldman Sachs
- Piper Sandler
- …and hundreds of others